However, GS patients had significantly lower BMI (22.8 vs. 25.4 kg/m2), blood glucose levels (81.0 vs. 86 mg/dL), insulin (4.1 vs. 5.9 μU/mL), C-peptide (1.2 vs. 1.4 ng/mL), and triacylglycerols (73 vs. 85 mg/dL), indicating that they are leaner and healthier and thus less prone to metabolic diseases or premature death. This evidence concerns the gene INS and metabolic disease.